Skip to main content

Table 5 Immunogenicity—total incidence of ADAs

From: Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

 Antibody positive by week 22 with a negative or no result at baselineAntibody positive post week 22 with a negative or no result at week 22
ABP 710RPABP 710/ABP 710RP/RPRP/ABP 710
Number of patients261264964545
Binding antibody, n (%)149 (57.1)160 (60.6)29 (30.2)19 (42.2)18 (40.0)
Neutralizing antibody, n (%)47 (18.0)55 (20.8)3 (3.1)1 (2.2)2 (4.4)
  1. Abbreviations: ADA antidrug antibody, RP reference product